GLP-1 Meds and Pregnancy: What the Research Shows

If you are a woman of childbearing age taking a GLP-1 medication for weight loss or type 2 diabetes, you have probably wondered what happens if you get pregnant. Specifically, whether these medications could raise your risk of complications. A new cohort study offers some early reassurance on one important front: hypertensive disorders of pregnancy.

What the Study Looked At

Researchers examined a group of women who were exposed to GLP-1 receptor agonists (GLP-1 RAs) during the peripregnancy period. That term refers to the window of time immediately before conception or in the very early weeks of pregnancy, before many women even know they are pregnant.

The primary question was whether that exposure was tied to a higher rate of hypertensive disorders of pregnancy (HDP). This category includes conditions like gestational hypertension and preeclampsia, which are serious complications that can affect both mother and baby.

After analyzing the cohort data, investigators found no statistically significant link between peripregnancy GLP-1 exposure and increased rates of these hypertensive conditions.

Why This Question Matters

Women with obesity or type 2 diabetes already face a higher baseline risk of hypertensive disorders during pregnancy. Since GLP-1 medications are increasingly used by this population, understanding whether the drugs themselves add to that risk is clinically important. This study suggests they may not, at least with respect to HDP.

What GLP-1 Receptor Agonists Are

GLP-1 receptor agonists are a class of medications that mimic a natural hormone called glucagon-like peptide-1. That hormone signals the pancreas to release insulin, slows digestion, and reduces appetite.

The most widely used GLP-1 medications right now include:

• Semaglutide, sold as Ozempic for type 2 diabetes management and as Wegovy for chronic weight management, both administered as once-weekly subcutaneous injections, and as Rybelsus in oral tablet form for type 2 diabetes.
• Tirzepatide, sold as Mounjaro for type 2 diabetes and as Zepbound for chronic weight management, also administered as a once-weekly subcutaneous injection, and notable for targeting both GLP-1 and GIP receptors simultaneously.
• Liraglutide, an older GLP-1 receptor agonist sold as Victoza for type 2 diabetes and as Saxenda for weight management, administered as a daily injection and representing an earlier generation of the drug class with a shorter half-life than semaglutide.

These medications have become some of the most prescribed drugs in the country. As their use has expanded to younger, reproductive-age women, pregnancy safety questions have become increasingly urgent.

Current Official Guidelines on GLP-1 Use During Pregnancy

It is important to separate what this new study found from what current medical guidelines actually recommend. They are not the same thing.

Right now, the FDA has not approved any GLP-1 receptor agonist for use during pregnancy. Animal studies have raised some concerns about fetal development at high doses, though those findings do not always translate directly to humans.

Standard clinical guidance recommends that women stop GLP-1 medications before trying to conceive. Specifically, the general recommendation for semaglutide is to discontinue it at least two months before a planned pregnancy, given how long the drug stays in the body.

What "Peripregnancy Exposure" Actually Means

In research, "peripregnancy" exposure typically means the drug was present in the body around the time of conception or in the earliest weeks of pregnancy. This often happens when a pregnancy is unplanned or when a woman stops the medication as soon as she finds out she is pregnant.

This study addressed that real-world scenario directly, which is part of what makes it clinically relevant. Unplanned pregnancies happen, and providers need data to counsel patients appropriately.

Hypertensive Disorders of Pregnancy: A Quick Primer

Hypertensive disorders of pregnancy are a group of conditions defined by elevated blood pressure during pregnancy. They affect roughly 10% of pregnancies globally and are a leading cause of maternal and fetal complications.

Women with obesity are at significantly higher risk for all of these conditions. Since GLP-1 medications are commonly prescribed for obesity management, the overlap in patient populations makes this safety question especially important.

What the Study Does Not Tell Us

This finding is encouraging, but it is not a green light to continue GLP-1 medications through pregnancy. Here is what the study cannot fully address:

It focused on one specific outcome. Hypertensive disorders are just one potential concern during pregnancy. This study does not provide safety data on fetal development, birth weight, preterm birth, or other outcomes.

Cohort studies have limitations. Observational research can identify associations, but it cannot prove causation. Confounding factors, meaning other variables that could influence outcomes, are always a challenge in this type of research.

Long-term data is still limited. GLP-1 medications are relatively new in widespread use. We do not yet have long-term follow-up data on children born to mothers who had peripregnancy exposure.

Sample sizes and study design vary. Until findings are replicated across multiple large populations, any single study should be interpreted with appropriate caution.

What This Means for Women Currently on GLP-1 Therapy

If you are taking a GLP-1 medication and are of childbearing age, this study is relevant background information. But it should not change your approach without input from your healthcare provider.

Here is a practical framework for thinking about your situation:

If You Are Actively Trying to Conceive

Talk to your doctor now about a discontinuation plan. Current guidelines still recommend stopping GLP-1 medications before trying to conceive. Ask specifically how far in advance you need to stop based on which medication you are taking, since different drugs have different half-lives (how long they stay active in your body).

Semaglutide, for example, has a much longer half-life than older GLP-1 medications, which is why the recommended washout period is longer.

If You Are Not Trying to Conceive

Reliable contraception is typically recommended for women on GLP-1 therapy who want to avoid pregnancy. Some GLP-1 medications may also affect how oral contraceptives are absorbed due to their effects on gastric emptying. Ask your provider whether your current contraception method is still reliably effective.

If You Found Out You Are Pregnant While on a GLP-1 Med

Do not panic, but do call your healthcare provider right away. Do not just stop the medication cold without guidance. Your provider will want to assess your specific situation, confirm the timing of your last dose, and determine next steps for monitoring.

This study's findings provide some reassurance specifically about hypertensive risk, but your provider needs to evaluate the full picture.

Questions to Ask Your Doctor

Walking into an appointment prepared makes a real difference. Here are specific questions worth raising if you are a woman on GLP-1 therapy:

• How far in advance of trying to conceive do I need to stop my specific GLP-1 medication, given that different drugs have different half-lives and washout periods?
• What is the recommended contraception approach for women on GLP-1 therapy, and does my current contraception method remain reliably effective given how these medications affect gastric emptying and oral contraceptive absorption?
• If I become pregnant unexpectedly while still on a GLP-1 medication, what is the exact protocol you want me to follow, including whether to stop immediately, how quickly to contact your office, and what monitoring would be needed?
• What does the new cohort research on peripregnancy GLP-1 exposure and hypertensive disorders mean for how you counsel patients like me, and does it change your recommendation about the timing of discontinuation?
• Are there any metabolic or weight management alternatives you would recommend during the period between stopping my GLP-1 medication and trying to conceive, to help maintain my health outcomes during the washout window?
• If I have a history of gestational hypertension or preeclampsia in a prior pregnancy, does that change how you think about my GLP-1 use and the timing of discontinuation before a future pregnancy?
• Are there any pregnancy registries or ongoing studies tracking outcomes in women with peripregnancy GLP-1 exposure that I could contribute to or benefit from as additional safety data becomes available?

Having this conversation now is far better than navigating a stressful situation without information.

The Bigger Picture: Growing Safety Research

The study on peripregnancy GLP-1 exposure and hypertensive disorders is part of a broader and accelerating wave of real-world safety research on these medications. As prescriptions have surged, researchers have been working to close the knowledge gaps that exist because pregnant women are routinely excluded from clinical drug trials.

This exclusion is standard practice for ethical reasons, but it creates a real-world problem: millions of women of reproductive age are now using these drugs, and the evidence base for pregnancy safety lags far behind the prescribing rates.

The good news is that pharmacovigilance databases, insurance claims data, and registry studies are beginning to generate meaningful cohort data. This new study is one piece of that growing puzzle.

Researchers, clinicians, and patient advocates are calling for dedicated pregnancy registries for GLP-1 medications to build a more complete picture over time. Several are already underway.